1. Mohammad Khalil, RPh, PhD
ACDIMA at Glance
Mohammad Khalil, RPh, PhD
Director General

2. Investing for Nations Wealth and Health
ACDIMA is a Pan-Arab shareholding company established by a resolution from the Arab Economic Unity Council on March 6th 1976 and headquartered in Amman-Jordan.
With its multinational presentation, ACDIMA embarks on successful business strategy that aligns with national agendas for medicine security. Globally, ACDIMA builds relations that create values to assist in setting up seamless projects in the Arab World.

3. ACDIMA’s Visionary Leadership His Excellency Saleh Al-Khlaiwi
“The Arab Company for Drug Industry and Medical Appliances (ACDIMA) was instituted in 1976 with a total capital of USD 300,000,000 invested by 17 governments of Arab Countries. In its establishment doctrine, ACDIMA’s Board of Directors approved a strategy that aims at boosting investments in diversified pharmaceutical projects of on-demand feasibility and unique value. With integrated-resources approach, ACDIMA seeks to stimulate investors to set up joint pharmaceutical projects that exploit advanced technologies in the Arab World. Our targeted operations span over 10 countries and are conducted through three business segments to broaden our economic contribution.”
“Supporting new entrepreneurships while ensuring sustainable long-term growth and legacy business development will allow us reaping the fruits of our flourishing long-standing partnerships.”
His Excellency Saleh Al-Khlaiwi
Chairman of the Board of Directors
Kingdom of Saudi Arabia

4. Consolidated Mission of Multinational Board of Directors
Dr. Hammodi Hameed
Member of the Board Republic of Iraq
Ms. Sheikha Khalifa Ben Zaal
Member of the Board United Arab Emirates
Dr. Ali Zawawu
Member of the Board Kingdom of Saudi Arabia
Mr. Omar Al-Hamed
Vice Chairman of the Board State of Qatar
Mr.Adil Kareem
Member of the Board Republic of Iraq

5. ACDIMA’s Deployed Strategy for Growth
“Since its foundation, ACDIMA plays a vital role in translating the cooperative model between different countries. We transform the vision into reality with strong determination and faithful thrill; and … with insightful strategic mindsets we seize opportunities to reform the shape and anchor on new shores.”
“Leading the race and ever striving to extend the boundaries are the obsessive mission of successful corporates. We believe in the power of knowledge and the synergism of partnerships. Developing our skilled workforce leverages our position in the marketplace.”
“We’ll keep the pledge and ramp up the efforts for revolutionary growth.”
Mohammad Khalil, PhD
Director General
Hashemite Kingdom of Jordan

6. For more than 40 years… Where are we and what we do?

7. Hashemite Kingdom of Jordan (HKJ)
ACDIMA Center for Bioequivalence and Pharmaceutical Studies (ACDIMA BioCenter)
Hashemite Kingdom of Jordan (HKJ)
ACDIMA BioCenter is a state-of-the-art Contract Research Organisation (CRO), established by ACDIMA to provide principally bioequivalence testing services to the pharmaceutical industry. ACDIMA BioCenter was founded in 2000 and headquartered in Amman-Jordan. It underwent successive expansion plans and now considered the largest CRO in the MENA region.
ACDIMA BioCenter provides services to pharmaceutical companies in the GCC, MENA, Latin America and Europe according to international GCP and GLP requirements.

8. Saudi Pharmaceutical Industries and Medical Appliances (SPIMACO) Kingdom of Saudi Arabia (KSA)
SPIMACO is one the major pharmaceutical companies in the Arab World, which continues to strengthen its investments.
It currently has expansions projects in its factories which are expected to be completed by the end of 2016.
The Company owns several companies including ARAC and contributes in many other companies, including ENAYA, TAPHCO, CAD, EirGen Pharma, lPharma, and Dammam Pharma.

9. Gulf Pharmaceutical Industries (JULPHAR) & JULPHAR Diabetes
United Arab Emirates (UAE)
JULPHAR is one of the leading manufacturers of pharmaceuticals in the Middle East. Its registered products exceed 3,600 products in more than 50 countries. Moreover, a new factory for JULPHAR was inaugurated in Ethiopia. This step reflects the ambitious expansion plans of the Company in the emerging markets. Two factories were also set up in Algeria and Saudi Arabia.
The achievements of the company include setting up a factory for manufacturing insulin, at a cost of about USD 180 Million. In addition, the company has been engaged in manufacturing medical devices, such as the electronic device for continuous monitoring of insulin levels in the human body.

10. Société Arabe Des Industries Pharmaceutiques (SAIPH)
Republic of Tunisia
ACDIMA owns 68.1% in the capital of SAIPH, one of the top pharmaceutical companies in North Africa and represents a real link between South, North, East and West. 
SAIPH is the first exporter laboratory in its field. With more than 20,000m2 of manufacturing area, SAIPH is producing generic and under-license products (Sanofi, Abbott, Servier, Merck, Minarelli ) in all therapeutic areas. 

11. Arab Company for Antibiotics Industries (ACAI)
Republic of Iraq
The company manufactures penicillins and cephalosporins as dry suspension, solid and injectable forms.

12. Industrie Pharmaceutique Arabo (IPharma)
Kingdom of Morocco
ACDIMA owns 21% in the share capital of IPharma, estimated at MAD 100 Million.
Along with the two major partners, SPIMACO and Cooper Pharma, IPharma expanded its production range in the Moroccan market.

13. Arab Company for Pharmaceutical Products (ARABIO)
Kingdom of Saudi Arabia (KSA)
ARABIO was founded in 2007 with a capital of SAR 186,000,000. ACDIMA owns 31.38% in the capital of this Company.
The main objective of the company is manufacturing and marketing vaccines and biological products, in addition to conducting research leading to the discovery of new products. The production program consists of injection lines, liquid containers, and dried containers to produce vaccines for seasonal influenza, hepatitis and meningitis. Moreover, ARABIO targets producing other vaccines in the future, such as rotavirus, measles and other vaccines.

14. CAD Middle East Pharmaceutical Industries
Kingdom of Saudi Arabia (KSA)
The Company was established in 2006 with a capital of SAR 73,000,000. The production program of the company is designed to manufacture (21) active raw materials.
The engineering and pharmaceutical layout has designed the factory of this company so that its production capacity of the active raw materials will nearly be 118 tons/year. The production of this company will support the Arab pharmaceutical industry with active raw materials included in the production program of the project.

15. Saudi AJAL Company for Health Services & Commercial Investment
Kingdom of Saudi Arabia (KSA)
Saudi AJAL Company was established in 2008 in The Kingdom of Saudi Arabia and ACDIMA acquired 20% of the company's capital in 2014.
The company aims at acquiring, managing and maintaining hospitals, medical centers, medical laboratories, bioequivalence centers, and medical and pharmaceuticals consultation centers, in addition to investing in unique pharmaceutical projects. Currently Saudi AJAL possesses a state-of-the-art CRO that is licensed to provide bioequivalence studies in KSA, in addition to clinical trials.

16. The Arab Company for Veterinary Medicine Production (ACVMP)
Republic of Sudan
The capital of this Company is USD 37,000,000. ACDIMA owns 40% of ACVMP capital.
It was designed to produce solid, liquid and injectable veterinary medicine products

17. ACDIMA for Veterinary Medicines Industry (ACDIVET)
Syrian Arab Republic
ACDIMA For Veterinary Medicines Industry (ACDIVET) has been founded since 1999 as first-in-kind investment for ACDIMA in the veterinary sector.
ACDIVET exploited ACDIMA’s long experience in the human medicine. The company is equipped to manufacture different pharmaceutical forms in various therapeutic  categories of veterinary products such as injections, syrups, powders and tablets), according to international standards of cGMP requirements

18. Shamra Pharma Dental Anesthetic Company
Syrian Arab Republic
ACDIMA owns 43.9% in the share capital of Shamra Pharma which amounts to SYP ,000.
The production of the company has been suspended since June 2012, due to the prevailing circumstances in the Syrian Arab Republic.

19. Tassili Arab Pharmaceutical Company (TAPHCO)
Algeria
This company was inaugurated in 2015 and ready now for operation. ACDIMA owns 28.98% in its capital.
The company is a state of art company for various generic pharmaceutical products.

20. Al-Arabiya for Medical Solutions and Medicines
Republic of Libya
This company is still under construction
Office: Fax: Mobile: /
P.O. Box: Amman Jordan
Mohammad Khalil, PhD
Director General

21. Mohammad Khalil, RPh, PhD
With compliments
Mohammad Khalil, RPh, PhD
Director General